Profile | GDS2987 / GI_13994288-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 27.8 | 63 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 46.4 | 70 |
GSM215254 | HMVEC_atorvastatin_rep1 | 57.9 | 70 |
GSM215282 | HMVEC_atorvastatin_rep3 | 29.6 | 55 |
GSM215344 | HMVEC_atorvastatin_rep2 | 40.2 | 64 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 39.1 | 58 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 20.6 | 39 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 41 | 69 |
GSM215295 | HMVEC_SLx2119_rep2 | 40.4 | 60 |
GSM215296 | HMVEC_SLx2119_rep3 | 18 | 30 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 24.5 | 37 |
GSM215311 | PASMC_atorvastatin_rep1 | 40.5 | 56 |
GSM215312 | PASMC_atorvastatin_rep2 | 24.5 | 37 |
GSM215313 | PASMC_atorvastatin_rep3 | 53.5 | 60 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 58 | 65 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 19.6 | 36 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 45.3 | 59 |
GSM215327 | PASMC_SLx2119_rep1 | 18.4 | 32 |
GSM215328 | PASMC_SLx2119_rep2 | 61.8 | 68 |
GSM215329 | PASMC_SLx2119_rep3 | 34.6 | 54 |
GSM215330 | Fibroblasts_vehicle_rep1 | 11.3 | 27 |
GSM215331 | Fibroblasts_vehicle_rep2 | 8.9 | 25 |
GSM215332 | Fibroblasts_vehicle_rep3 | 16.3 | 47 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 27.9 | 57 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 42.2 | 66 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 69.3 | 71 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 12 | 37 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 29.9 | 63 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 15.4 | 40 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 10.2 | 30 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 26.7 | 57 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 39.1 | 64 |